Citigroup’s Immunovant IMVT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.5M Buy
74,000
+54,000
+270% +$2.13M ﹤0.01% 2644
2026
Q2
$771K Buy
+20,000
New +$609K ﹤0.01% 3638
2025
Q2
– Sell
-59,200
Closed -$1.01M – 5770
2025
Q1
$1.01M Hold
59,200
– – ﹤0.01% 3255
2024
Q4
$1.47M Buy
59,200
+29,700
+101% +$842K ﹤0.01% 3061
2024
Q3
$841K Buy
+29,500
New +$870K ﹤0.01% 3393
2023
Q2
– Sell
-38,900
Closed -$603K – 5637
2023
Q1
$603K Buy
+38,900
New +$675K ﹤0.01% 2981

Other funds holding IMVT

Citigroup's IMVT Position: Q3 2026 in Review

Citigroup reduced its Immunovant (IMVT) stake by 58% in Q3 2026, selling an estimated $2.64M and leaving 49,254 shares worth $1.66M. The position accounts for ﹤0.01% of the portfolio, ranked #2959.

Citigroup first reported a position in IMVT in Q1 2020 and has held it in 27 quarters since. The position peaked at $8.07M in Q1 2024. 53 funds tracked by Wall St. Rank hold IMVT as of Q3 2026.

  • Citigroup held 49,254 shares of Immunovant worth $1.66M as of Q3 2026.
  • Citigroup sold 66,891 Immunovant shares in Q3 2026, an estimated $2.64M.
  • Immunovant made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #2959 holding.
  • Citigroup first reported a position in Immunovant in Q1 2020 and has held it in 27 quarters since.
  • Citigroup's Immunovant position peaked at $8.07M in Q1 2024.
  • 53 funds tracked by Wall St. Rank held Immunovant as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.